OGN

NEUTRALM&A

Organon & Co.

2026-07-30

Price

$13.55

+0.07%

This is the 2026-07-30 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score6.0Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

Organon's price action is fundamentally anchored by its pending $14.00 per share all-cash acquisition by Sun Pharma. Technical signals like QUIET_STORM and PERFECT_STACK perfectly capture this M&A arbitrage environment, reflecting the stock's exceptionally low 3.3% volatility and steady institutional absorption. While the broader market faces a CAUTION (RATES) regime with an elevated VIX and hawkish Fed policy, OGN remains structurally insulated as deal markets look past the macro noise. Recent shareholder approval has further de-risked the transaction, leaving only regulatory clearance to close the remaining arbitrage spread.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: OGN is a pure merger arbitrage play targeting the $14.00 cash buyout price from Sun Pharma, offering a highly insulated return profile.
Key Risk: Regulatory pushback or delayed closing timelines, which could weigh on the stock's time-value given the 3.63% Fed Funds rate.
What to Watch: Regulatory clearance updates and adherence to the $13.48 support, which serves as the floor for arbitrageurs.

← Back to 2026-07-30 View Full OGN History →Yahoo Finance &nearr;